538 related articles for article (PubMed ID: 19446929)
1. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
[TBL] [Abstract][Full Text] [Related]
2. Trypanosoma cruzi: a novel chemical class (nitrobenzofurans) active against infections of mice (Mus musculus).
Kinnamon KE; Poon BT; Hanson WL; Waits VB
Exp Parasitol; 1998 Jun; 89(2):251-6. PubMed ID: 9635449
[No Abstract] [Full Text] [Related]
3. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.
Moraes CB; White KL; Braillard S; Perez C; Goo J; Gaspar L; Shackleford DM; Cordeiro-da-Silva A; Thompson RC; Freitas-Junior L; Charman SA; Chatelain E
Antimicrob Agents Chemother; 2015; 59(6):3645-7. PubMed ID: 25845874
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
5. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling studies and in vitro bioactivity evaluation of a set of novel 5-nitro-heterocyclic derivatives as anti-T. cruzi agents.
Paula FR; Jorge SD; de Almeida LV; Pasqualoto KF; Tavares LC
Bioorg Med Chem; 2009 Apr; 17(7):2673-9. PubMed ID: 19303308
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
Andrade SG; Magalhães JB; Pontes AL
Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
[TBL] [Abstract][Full Text] [Related]
8. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
10. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?
Boiani M; Piacenza L; Hernández P; Boiani L; Cerecetto H; González M; Denicola A
Biochem Pharmacol; 2010 Jun; 79(12):1736-45. PubMed ID: 20178775
[TBL] [Abstract][Full Text] [Related]
11. The urgent need to develop new drugs and tools for the treatment of Chagas disease.
Muñoz MJ; Murcia L; Segovia M
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):5-7. PubMed ID: 21171870
[No Abstract] [Full Text] [Related]
12. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies.
Rodríguez J; Arán VJ; Boiani L; Olea-Azar C; Lavaggi ML; González M; Cerecetto H; Maya JD; Carrasco-Pozo C; Cosoy HS
Bioorg Med Chem; 2009 Dec; 17(24):8186-96. PubMed ID: 19900812
[TBL] [Abstract][Full Text] [Related]
13. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
14. [Etiological treatment of Chagas' disease].
Rassi A
Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
[No Abstract] [Full Text] [Related]
15. Synthesis, in vitro evaluation, and SAR studies of a potential antichagasic 1H-pyrazolo[3,4-b]pyridine series.
Dias LR; Santos MB; Albuquerque Sd; Castro HC; de Souza AM; Freitas AC; DiVaio MA; Cabral LM; Rodrigues CR
Bioorg Med Chem; 2007 Jan; 15(1):211-9. PubMed ID: 17064907
[TBL] [Abstract][Full Text] [Related]
16. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
Chambó JG; Cabeza Meckert PM; Laguens RP
Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
[No Abstract] [Full Text] [Related]
17. 2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
Boiani M; Boiani L; Denicola A; Torres de Ortiz S; Serna E; Vera de Bilbao N; Sanabria L; Yaluff G; Nakayama H; Rojas de Arias A; Vega C; Rolan M; Gómez-Barrio A; Cerecetto H; Gonzalez M
J Med Chem; 2006 Jun; 49(11):3215-24. PubMed ID: 16722639
[TBL] [Abstract][Full Text] [Related]
18. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
Gerpe A; Alvarez G; Benítez D; Boiani L; Quiroga M; Hernández P; Sortino M; Zacchino S; González M; Cerecetto H
Bioorg Med Chem; 2009 Nov; 17(21):7500-9. PubMed ID: 19811923
[TBL] [Abstract][Full Text] [Related]
19. In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
Boiani L; Davies C; Arredondo C; Porcal W; Merlino A; Gerpe A; Boiani M; Pacheco JP; Basombrío MA; Cerecetto H; González M
Eur J Med Chem; 2008 Oct; 43(10):2229-37. PubMed ID: 18255195
[TBL] [Abstract][Full Text] [Related]
20. Activity of "reversed" diamidines against Trypanosoma cruzi "in vitro".
Silva CF; Batista MM; Mota RA; de Souza EM; Stephens CE; Som P; Boykin DW; Soeiro Mde N
Biochem Pharmacol; 2007 Jun; 73(12):1939-46. PubMed ID: 17462605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
